Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Besifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.88 |
| ▸ | POLB | P06746 | 2/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.88 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 7/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.49 |
| ▸ | TOP1 | P11387 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Besifloxacin SCHEMBL725805 | 1.00 | ALDH1A1 (0.88) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL5959095 | 1.00 | ALDH1A1 (0.88) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL29359545 | 0.99 | ALDH1A1 (0.86) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL28011379 | 0.99 | ALDH1A1 (0.86) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL291598 | 0.99 | ALDH1A1 (0.86) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL33959 | 0.93 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL8596801 | 0.93 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL33960 | 0.93 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL29360508 | 0.93 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL193233 | 0.93 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395215-B1 | QUINOLONE CARBOXYLIC ACID COMPOSITIONS AND RELATED METHODS OF TREATMENT | BAUSCH & LOMB (US) | 2014-03-19 | — | — | EP | claimed |
| US-20130310557-A1 | Amorphous Besifloxacin Solid | BAUSCH & LOMB (US) | 2013-11-21 | — | — | US | claimed |
| US-8518935-B2 | Amorphous besifloxacin solid | BAUSCH & LOMB INCORPORATED (US) | 2013-08-27 | — | — | US | claimed |
| US-8481526-B2 | Fluoroquinolone carboxylic acid molecular crystals | BAUSCH & LOMB INCORPORATED (US) | 2013-07-09 | — | — | US | claimed |
| US-20040157825-A1 | Quinolone carboxylic acid compositions and related methods of treatment | BAUSCH & LOMB INCORPORATED | 2004-08-12 | — | — | US | claimed |
| US-6699492-B2 | ESPECIALLY A SUSTAINED RELEASE COMPOSITION FOR THE TREATMENT OF OCULAR AND PERIOCULAR INFECTIONS. | INSITE VISION INCORPORATED | 2004-03-02 | — | — | US | claimed |
| US-6685958-B2 | E.G., 7-(3-AMINO-2,3,4,5,6,7-HEXAHYDRO-1H-AZEPIN-1-YL)-8-CHLORO-1-CYCLOPROPYL-6 -FLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID; TREATMENT OF OCULAR AND PERIOCULAR INFECTIONS. | INSITE VISION INCORPORATED | 2004-02-03 | — | — | US | claimed |
| US-20020187193-A1 | Quinolone carboxylic acid compositions and related methods of treatment | ORAPHARMA, INC. | 2002-12-12 | — | — | US | claimed |
| US-20020182255-A1 | Quinolone carboxylic acid compositions and related methods of treatment | SALIX PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20250114373-A1 | INTRACANALICULAR INSERT COMPRISING AN ANTIMICROBIAL AGENT | OCULAR THERAPEUTIX, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-118804742-A | Intratubular insert comprising antimicrobial agent | 视尔普斯眼科公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133278-A1 | INTRACANALICULAR INSERT COMPRISING AN ANTIMICROBIAL AGENT | OCULAR THERAPEUTIX, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-108815119-B | Pharmaceutical composition containing besifloxacin hydrochloride and preparation method thereof | 江苏亚邦爱普森药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-8937062-B2 | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria | BAUSCH & LOMB INCORPORATED (US) | 2015-01-20 | — | — | US | disclosed |
| EP-1395215-A1 | QUINOLONE CARBOXYLIC ACID COMPOSITIONS AND RELATED METHODS OF TREATMENT | INSITE VISION INCORPORATED (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6699492-B2 | ESPECIALLY A SUSTAINED RELEASE COMPOSITION FOR THE TREATMENT OF OCULAR AND PERIOCULAR INFECTIONS. | INSITE VISION INCORPORATED | 2004-03-02 | — | — | US | disclosed |
| US-6685958-B2 | E.G., 7-(3-AMINO-2,3,4,5,6,7-HEXAHYDRO-1H-AZEPIN-1-YL)-8-CHLORO-1-CYCLOPROPYL-6 -FLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID; TREATMENT OF OCULAR AND PERIOCULAR INFECTIONS. | INSITE VISION INCORPORATED | 2004-02-03 | — | — | US | disclosed |
| WO-2002100309-A1 | QUINOLONE CARBOXYLIC ACID COMPOSITIONS AND RELATED METHODS OF TREATMENT | INSITE VISION INCORPORATED (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020187193-A1 | Quinolone carboxylic acid compositions and related methods of treatment | ORAPHARMA, INC. | 2002-12-12 | — | — | US | disclosed |
| US-20020182255-A1 | Quinolone carboxylic acid compositions and related methods of treatment | SALIX PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187193-A1 | Quinolone carboxylic acid compositions and related methods of treatment | NQO2, QPCT, QARS1 | ALDH1A1 957/4885POLB 2663/4885OPRM1 2498/4885 |
| US-20040157825-A1 | Quinolone carboxylic acid compositions and related methods of treatment | NQO2, QPCT, QARS1 | ALDH1A1 957/4885POLB 2663/4885OPRM1 2498/4885 |
| US-20020182255-A1 | Quinolone carboxylic acid compositions and related methods of treatment | NQO2, QPCT, QARS1 | ALDH1A1 957/4885POLB 2663/4885OPRM1 2498/4885 |
| US-20130310557-A1 | Amorphous Besifloxacin Solid | ABCG2, YBX1, SP1 | ALDH1A1 2100/4885POLB 1837/4885OPRM1 868/4885 |
| US-20250114373-A1 | INTRACANALICULAR INSERT COMPRISING AN ANTIMICROBIAL AGENT | ABCB11, IDE, YIF1A | ALDH1A1 271/4885POLB 3072/4885OPRM1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.